

Daniel Shepshelovich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6771959/publications.pdf>

Version: 2024-02-01

87
papers

1,102
citations

471509

17
h-index

477307

29
g-index

90
all docs

90
docs citations

90
times ranked

1663
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid 8â€Zone Lung Ultrasound Protocol is Comparable to a Full 12â€Zone Protocol for Outcome Prediction in Hospitalized <sc>COVID</sc>â€19 Patients. Journal of Ultrasound in Medicine, 2022, 41, 1677-1687.	1.7	7
2	Absence of hemoglobin increase is associated with reduced graft survival after kidney transplantation. Clinical Transplantation, 2022, 36, e14602.	1.6	3
3	Emergency Use Authorizations of COVID-19â€Related Medical Products. JAMA Internal Medicine, 2022, 182, 228.	5.1	12
4	Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria. Clinical Infectious Diseases, 2021, 72, 1968-1974.	5.8	18
5	The clinical importance of early acute hepatic porphyria diagnosis: a national cohort. Internal and Emergency Medicine, 2021, 16, 133-139.	2.0	10
6	Vaccine safety â€ is the SARS-CoV-2 vaccine any different?. Human Vaccines and Immunotherapeutics, 2021, 17, 1322-1325.	3.3	7
7	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer, 2021, 152, 58-65.	2.0	22
8	Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap. Infectious Diseases and Therapy, 2021, 10, 621-630.	4.0	10
9	Incidence of lung cancer following pneumonia in smokers: a population-based study. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.5	2
10	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. Journal of the National Cancer Institute, 2021, 113, 980-988.	6.3	25
11	Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology, 2021, , .	1.9	1
12	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 1086-1086.	1.6	0
13	Patient experience of early high grade symptomatic adverse events on early phase clinical trials using the PRO-CTCAE.. Journal of Clinical Oncology, 2021, 39, 12051-12051.	1.6	0
14	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. Journal of Clinical Oncology, 2021, 39, 6571-6571.	1.6	0
15	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2415-2418.	3.0	7
16	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. Cancer Treatment Reviews, 2021, 100, 102293.	7.7	3
17	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Annals of Hematology, 2021, 100, 2879-2887.	1.8	3
18	Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. European Journal of Internal Medicine, 2020, 71, 45-49.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. <i>Acta Haematologica</i> , 2020, 143, 73-77.	1.4	2
20	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 469-472.	2.3	0
21	Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients. <i>Age and Ageing</i> , 2020, 49, 26-31.	1.6	11
22	The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 534-545.	3.4	12
23	Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions. <i>Acta Haematologica</i> , 2020, 143, 446-451.	1.4	2
24	Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration. <i>Annals of Internal Medicine</i> , 2020, 173, 445-449.	3.9	13
25	Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications. <i>JAMA Internal Medicine</i> , 2020, 180, 1420.	5.1	13
26	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
27	Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration. <i>Leukemia and Lymphoma</i> , 2020, 61, 2216-2220.	1.3	2
28	Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. <i>Hematological Oncology</i> , 2020, 38, 584-588.	1.7	24
29	Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2020, 130, 56-63.	1.6	12
30	Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2014-2014.	1.6	2
31	Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma: a SEER population-based study. <i>Oncotarget</i> , 2020, 11, 4438-4447.	1.8	4
32	Risk Factors and Outcome of Polymicrobial Bacteremia: A Retrospective Cohort Study. <i>Israel Medical Association Journal</i> , 2020, 22, 279-284.	0.1	3
33	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1594-1607.	1.1	81
34	Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. <i>Molecular Carcinogenesis</i> , 2019, 58, 1960-1973.	2.7	1
35	Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey. <i>Transplant Infectious Disease</i> , 2019, 21, e13134.	1.7	8
36	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1228-1237.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Reporting infections in clinical trials of patients with haematological malignancies. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1494-1500.	6.0	14
38	Association Between Data Sources and US Food and Drug Administration Drug Safety Communications. <i>JAMA Internal Medicine</i> , 2019, 179, 1590.	5.1	18
39	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 531-545.	2.5	42
40	The association of vancomycin trough levels with outcomes among patients with methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections: Retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0214309.	2.5	5
41	Post renal transplant anemia: severity, causes and their association with graft and patient survival. <i>BMC Nephrology</i> , 2019, 20, 51.	1.8	32
42	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	3.7	23
43	Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2272-2276.	3.0	7
44	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	3.0	10
45	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	7.1	2
46	Reporting of patient reported outcome (PRO) in clinical trials: A systematic review of clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6590-6590.	1.6	1
47	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 524-524.	1.6	0
48	Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1562-1562.	1.6	0
49	Molecular-based diagnosis of <i>Clostridium difficile</i> infection is associated with reduced mortality. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1137-1142.	2.9	14
50	Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All. <i>Journal of Thoracic Oncology</i> , 2018, 13, 601-602.	1.1	0
51	Comparison of reporting phase III randomized controlled trials of antibiotic treatment for common bacterial infections in ClinicalTrials.gov and matched publications. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1211.e9-1211.e14.	6.0	10
52	Comparison of published and unpublished phase I clinical cancer trials: an analysis of the ClinicalTrials.gov database. <i>Investigational New Drugs</i> , 2018, 36, 933-938.	2.6	10
53	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	1.6	27
54	Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?. <i>Oncotarget</i> , 2018, 9, 30942-30943.	1.8	1

#	ARTICLE	IF	CITATIONS
55	Fcγ receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5478-5487.	2.8	19
56	Endocrinopathy-induced euvolemic hyponatremia. <i>Internal and Emergency Medicine</i> , 2018, 13, 679-688.	2.0	3
57	Agranulocytosis Associated with Waldenström Macroglobulinemia. <i>Acta Haematologica</i> , 2018, 140, 42-45.	1.4	2
58	The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-633.	1.6	0
59	Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18717-e18717.	1.6	0
60	Educational interventions encouraging appropriate use of blood transfusions. <i>Vox Sanguinis</i> , 2017, 112, 150-155.	1.5	7
61	Medication-induced SIADH: distribution and characterization according to medication class. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1801-1807.	2.4	67
62	Screening for occult cancer in idiopathic venous thromboembolism – Systemic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2017, 42, 74-80.	2.2	9
63	Chills During Hemodialysis: Prediction and Prevalence of Bacterial Infections – A Retrospective Cohort Study. <i>American Journal of Medicine</i> , 2017, 130, 477-481.	1.5	2
64	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. <i>Investigational New Drugs</i> , 2017, 35, 827-833.	2.6	9
65	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. <i>World Journal of Gastroenterology</i> , 2017, 23, 1387.	3.3	14
66	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-552.	1.6	0
67	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	1.5	5
68	Perception of prognosis of cancer patients by non-oncologists. <i>International Journal of Clinical Practice</i> , 2016, 70, 1027-1032.	1.7	9
69	Yield of workup for patients with idiopathic presentation of the syndrome of inappropriate antidiuretic hormone secretion. <i>European Journal of Internal Medicine</i> , 2016, 32, 60-64.	2.2	7
70	Malignancy associated SIADH: Characterization and clinical implications. <i>Acta Oncologica</i> , 2016, 55, 1190-1195.	1.8	20
71	Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 677-690.	1.9	189
72	Colorectal cancer in young patients: is it a distinct clinical entity?. <i>International Journal of Clinical Oncology</i> , 2016, 21, 684-695.	2.2	35

#	ARTICLE	IF	CITATIONS
73	High Lung Cancer Incidence in Heavy Smokers Following Hospitalization due to Pneumonia. American Journal of Medicine, 2016, 129, 332-338.	1.5	4
74	BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 2433-2454.	1.8	19
75	The association between antihypertensive medications and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, e12000-e12000.	1.6	0
76	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
77	The association between treatment for metabolic disorders and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, 527-527.	1.6	1
78	The syndrome of inappropriate antidiuretic hormone secretion: Distribution and characterization according to etiologies. European Journal of Internal Medicine, 2015, 26, 819-824.	2.2	36
79	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. British Journal of Clinical Pharmacology, 2015, 79, 685-691.	2.4	3
80	MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma. Leukemia Research, 2015, 39, 632-637.	0.8	11
81	Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Cancer Genetics, 2015, 208, 575-579.	0.4	12
82	BRCA1 and telomere dysfunction-implications for malignant transformation.. Journal of Clinical Oncology, 2015, 33, e12512-e12512.	1.6	1
83	Colorectal cancer in young patients: Is it a distinct clinical entity?. Journal of Clinical Oncology, 2015, 33, e14594-e14594.	1.6	0
84	Searching for the leak. American Journal of Hematology, 2014, 89, 928-930.	4.1	1
85	Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature. Acta Haematologica, 2014, 131, 227-230.	1.4	4
86	The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells. Biochemical and Biophysical Research Communications, 2014, 450, 274-282.	2.1	1
87	Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus, 2006, 15, 183-190.	1.6	55